<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals Ltd has submitted its annual disclosure for FY 2024-25 under SEBI's Large Corporate (LC) framework, as required by the SEBI circular dated November 26, 2018. The company has confirmed that it does NOT qualify as a 'Large Corporate' under the applicable criteria. Incremental borrowing in FY 2024-25 is reported as Nil, mandatory borrowing through debt securities is Not Applicable, and there is no shortfall or penalty. The disclosure was signed by Dhananjaya Alli, Executive Director, on April 30, 2025.
This is a routine regulatory compliance filing with no material impact on shareholders or the stock price. It simply confirms the company does not meet the SEBI threshold to be classified as a Large Corporate, meaning no mandatory debt securities borrowing requirement applies.